Eli Lilly has entered a non-exclusive agreement with digital health firm Rimidi to develop provider-focused tools for delivering personalised diabetes management solutions.
The collaboration is intended to enable effective insulin usage and optimised diabetes management while maintaining normal clinical workflow.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The firms plan to combine Rimidi’s diabetes management software platform with Eli Lilly’s integrated insulin management system that is in the development phase.
Rimidi CEO Lucienne Ide said: “Diabetes management is a collaborative effort between people with diabetes and their healthcare providers.
“With the right support, they can achieve better results together.”
Rimidi’s platform utilises individual characteristics and clinical histories of diabetes patients to detect people who could benefit from a particular management technique.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe platform runs on top of select electronic medical records systems to provide smooth workflow experience for point of care clinicians.
Lilly’s insulin management system is being developed to combine a connected insulin pen, glucose-sensing technologies and software applications to offer personalised recommendations on insulin dose.
The integrated system is part of the firm’s Connected Diabetes Ecosystem that is being developed to facilitate effective insulin usage for easy diabetes management.
The Ecosystem also includes an automated insulin delivery system that is designed as a hybrid closed-loop platform to leverage connected devices for automated insulin dosing.
Both of the Lilly’s systems are currently undergoing clinical trials and are expected to be commercialised in the coming two to three years.
